The prohibitions from the Treasury Department could cut off venture capital investors from a main source of new drugs for the ...
The Treasury Department’s proposed restrictions on U.S. investment in Chinese biopharma collide with Beijing’s new export ...
The Treasury Department proposed new rules Thursday to curb U.S. investment in Chinese biotechnology — just as American ...
A new proposal from the U.S. government seeking to address investment in Chinese biotech as a matter of national security ...
The Trump administration officially made biotechnology a national security concern late Thursday, proposing to subject ...
Biotech stocks are considered extremely high-risk, high-reward investments. Many biotech companies are developing one or more ...
It's been a horrible, lousy, rotten year so far for Alnylam Pharmaceuticals (ALNY-1.11%) investors. Feel free to add any ...
Completion of light dose-escalation Part A of Phase 1 study identifies regimen for further evaluation in Part B, supporting advancement of Padeliporfin VTP for treatment of locally advanced pancreatic ...
The sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still ...
Sartorius Stedim Biotech walked into Q3 2026 earnings priced for excellence, with the stock up roughly 25% over the past ...
The next generation of pharmaceutical and biotech MES will combine compliant execution, connected data, and better user ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results